Lung cancer metabolomic data from tumor core biopsies enables risk-score calculation for progression-free and overall survival.

ABSTRACT:

Introduction

Metabolomics has emerged as a powerful method to provide insight into cancer progression, including separating patients into low- and high-risk groups for overall (OS) and progression-free survival (PFS). However, survival prediction based mainly on metabolites obtained from biofluids remains elusive.

Objectives

This proof-of-concept study evaluates metabolites as biomarkers obtained directly from tumor core biopsies along with covariates age, sex, pathological stage at diagnosis (I/II vs. III/VI), histological subtype, and treatment vs. no treatment to risk stratify lung cancer patients in terms of OS and PFS.

Methods

Tumor core biopsy samples obtained during routine lung cancer patient care at the University of Louisville Hospital and Norton Hospital we

SUBMITTER: Miller HA 

PROVIDER: S-EPMC9724684 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature